Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend up since Jul 5 · below the Ichimoku cloud · RSI 46 · MACD above its signal
None of the 29 investors followed here reported a position in 6078.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 6078.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 13, 2026 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.48 per share. | 1.14M | $1.69M |
| May 10, 2026 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.53 per share. | 1.60M | $2.44M |
| May 7, 2026 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.53 per share. | 519K | $794.85K |
| May 6, 2026 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.51 per share. | 30.4K | $45.83K |
| Sep 17, 2025 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.78 per share. | 1.66M | $2.96M |
| Apr 6, 2025 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.65 per share. | 390.6K | $643.43K |
| Mar 30, 2025 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.72 per share. | 258.4K | $445.02K |
| Mar 27, 2025 | Zhu (Yiwen)Chief Executive Officer | Acquisition at price 1.80 per share. | 357K | $642.56K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.5 | 3.6 | -14.1 | 0.9 | -16.2 | -5.0 | 8.6 | 3.5 | -5.6 | -1.8 | −22.9% | ||
| 2025 | -11.2 | 16.2 | -8.9 | 4.5 | 9.1 | -0.4 | 12.1 | -12.5 | -4.3 | -8.6 | -3.4 | -2.0 | −13.4% |
| 2024 | -28.2 | 16.2 | 8.3 | 1.7 | 0.9 | -14.0 | -25.2 | -7.0 | 21.0 | -25.7 | -8.9 | -10.8 | −59.5% |
| 2023 | 10.6 | -7.9 | -2.2 | 3.0 | -19.9 | -7.9 | 18.7 | -21.3 | 10.7 | 7.6 | 1.8 | -26.6 | −37.0% |
| 2022 | -28.2 | 21.0 | -27.9 | 26.7 | 12.5 | 19.7 | -13.4 | -5.5 | 4.0 | -23.3 | 43.7 | 14.6 | +14.8% |
| 2021 | 22.1 | -5.9 | 0.1 | 8.2 | 47.0 | 13.6 | -24.0 | -22.2 | -3.6 | 18.1 | -11.6 | -19.5 | −0.6% |
| 2020 | 19.5 | 27.9 | 13.8 | 3.3 | 2.2 | 0.1 | +83.9% |
Hygeia Healthcare Holdings Co., Limited offers oncology healthcare services in the People's Republic of China. The company owns and operates private for-profit hospitals that provides oncology healthcare services, such as radiotherapy, surgery, and targeted therapy, as well as cancer diagnosis, treatment, and rehabilitation. It also provides radiotherapy services to third-party hospitals, including radiotherapy center consulting services, licensing of radiotherapy equipment for use in the radiotherapy centers, and maintenance and technical support services for radiotherapy equipment. In addition, the company provides management services to private not-for-profit hospitals, as well as supply chain services; sells pharmaceutical, medical consumables, and medical equipment to third parties; and produces proprietary SRT equipment. The company was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.
Buy / hold / sell counts
No recent headlines.